Melanoma and Skin Cancer
H e x a l AG supports clinical research in advanced and resected melanoma, including adjuvant treatment settings for stage IIB, IIC, and III disease, with a strong focus on pembrolizumab– and nivolumab-related biosimilar development.
- Advanced unresectable or metastatic melanoma
- Resected stage IIB, IIC, or III melanoma
- Adjuvant therapy in skin cancer
These studies reflect interest in immune checkpoint inhibition within both metastatic and earlier-stage oncology care.
Non-small-cell lung cancer
The sponsor is active in non-small-cell lung cancer research, including untreated metastatic disease, with clinical work centered on biosimilar versions of established PD-1 therapies used in oncology.
- Metastatic lung cancer
- PD-1 inhibitor biosimilars
- Comparative efficacy and safety assessment
This area links lung cancer treatment with evaluation of therapeutic similarity, safety, and immune response.
Multiple sclerosis
H e x a l AG also funds research in relapsing multiple sclerosis, including relapsing-remitting MS and active secondary progressive MS, through studies of ocrelizumab biosimilarity.
- Relapsing-remitting multiple sclerosis
- Active secondary progressive multiple sclerosis
- Ocrelizumab biosimilar development
The therapeutic emphasis extends beyond oncology into neuroimmunology and autoimmune disease.
Biosimilar immunotherapy
A major area of interest is the development of biosimilars to well-established immuno-oncology and immunology medicines, including agents related to pembrolizumab, nivolumab, and ocrelizumab.
- Checkpoint inhibitor biosimilars
- Monoclonal antibody comparability
- Immune response and immunogenicity
Research activity spans both cancer immunotherapy and neurologic autoimmune treatment.
